{"disease":{"id":"solid-tumor-or-lymphoma","name":"solid tumor or lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00840047","title":"Methionine PET/CT Studies In Patients With Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":503,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT04553692","title":"Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":272,"lead_sponsor_name":"IGM Biosciences, Inc.","has_results":false},{"nct_id":"NCT04458389","title":"A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":268,"lead_sponsor_name":"Tayu Huaxia Biotech Medical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05460767","title":"Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT03886831","title":"A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05374226","title":"A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT05842785","title":"TSN222 in Subjects With Advanced Solid Tumors or Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Tyligand Bioscience (Shanghai) Limited","has_results":false},{"nct_id":"NCT05607498","title":"First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"EpimAb Biotherapeutics (Suzhou)Co., Ltd.","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04718675","title":"A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":135,"lead_sponsor_name":"Kronos Bio","has_results":false},{"nct_id":"NCT03739931","title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"7 Hills Pharma, LLC","has_results":false},{"nct_id":"NCT06615193","title":"A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04711733","title":"Supportive Care Needs of Former Child, AYA Cancer Patients, and of Their Parents: Evaluation During Long-term Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT05115292","title":"A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"BJ Bioscience, Inc.","has_results":false},{"nct_id":"NCT00121719","title":"An Open Label Dose Escalation Study Of E7080","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT05892718","title":"A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"FBD Biologics Limited","has_results":false},{"nct_id":"NCT03323398","title":"Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT03657381","title":"Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT04094610","title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06445517","title":"Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"InSilico Medicine Hong Kong Limited","has_results":false},{"nct_id":"NCT06487624","title":"An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"FBD Biologics Limited","has_results":false},{"nct_id":"NCT05880043","title":"GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"GI Cell, Inc.","has_results":false},{"nct_id":"NCT02675439","title":"Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Chinook Therapeutics, Inc. (formerly Aduro)","has_results":false},{"nct_id":"NCT05564806","title":"Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"Eucure (Beijing) Biopharma Co., Ltd","has_results":false},{"nct_id":"NCT02214147","title":"Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05490043","title":"A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Antengene (Hangzhou) Biologics Co., Ltd.","has_results":false},{"nct_id":"NCT04986865","title":"A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Antengene Biologics Limited","has_results":false},{"nct_id":"NCT03458728","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT06073938","title":"Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT03403725","title":"MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Menarini Group","has_results":true},{"nct_id":"NCT02259010","title":"A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03526250","title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03445858","title":"Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT03698994","title":"Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03213665","title":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03210714","title":"Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03213678","title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03213652","title":"Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01327612","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03213704","title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03233204","title":"Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04284774","title":"Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03220035","title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03188328","title":"Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alfasigma S.p.A.","has_results":false},{"nct_id":"NCT04195555","title":"Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05271279","title":"A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Beijing Boren Hospital","has_results":false},{"nct_id":"NCT04320888","title":"Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}